Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
Our billing is certified by:
-
- PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole ... - MarketWatch (press release)
- PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole
- Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in ... - MarketWatch (press release)
- Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in
- Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H. pylori ... - News-Medical.net
- Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H
- POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results - MarketWatch (press release)
- POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial ResultsMarketWatch (press release)POZEN announced positive top-line results from two randomized, double-blind, multi-center, pivotal Phase 3 clinical trials of PA32540, a novel, coordinated-delivery tablet of immediate-release omeprazole (40 mg) and delayed release aspirin (325 mg)
- Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with ... - 7thSpace Interactive (press release)
- Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with
